SN vs. CTEC, HIK, INDV, HLN, MXCT, NIOX, CREO, EKF, BELL, and IUG
Should you be buying Smith & Nephew stock or one of its competitors? The main competitors of Smith & Nephew include ConvaTec Group (CTEC), Hikma Pharmaceuticals (HIK), Indivior (INDV), Haleon (HLN), MaxCyte (MXCT), NIOX Group (NIOX), Creo Medical Group (CREO), EKF Diagnostics (EKF), Belluscura (BELL), and Intelligent Ultrasound Group (IUG). These companies are all part of the "medical" sector.
Smith & Nephew (LON:SN) and ConvaTec Group (LON:CTEC) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking.
Smith & Nephew received 199 more outperform votes than ConvaTec Group when rated by MarketBeat users. However, 66.54% of users gave ConvaTec Group an outperform vote while only 61.70% of users gave Smith & Nephew an outperform vote.
Smith & Nephew has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, ConvaTec Group has a beta of 0.55, meaning that its stock price is 45% less volatile than the S&P 500.
ConvaTec Group has a net margin of 6.08% compared to Smith & Nephew's net margin of 4.74%. ConvaTec Group's return on equity of 7.89% beat Smith & Nephew's return on equity.
Smith & Nephew pays an annual dividend of GBX 30 per share and has a dividend yield of 3.0%. ConvaTec Group pays an annual dividend of GBX 5 per share and has a dividend yield of 1.7%. Smith & Nephew pays out 12,500.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. ConvaTec Group pays out 10,000.0% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
Smith & Nephew has higher revenue and earnings than ConvaTec Group. Smith & Nephew is trading at a lower price-to-earnings ratio than ConvaTec Group, indicating that it is currently the more affordable of the two stocks.
Smith & Nephew presently has a consensus target price of GBX 1,349.50, suggesting a potential upside of 36.09%. ConvaTec Group has a consensus target price of GBX 307.17, suggesting a potential upside of 7.25%. Given Smith & Nephew's higher possible upside, equities analysts clearly believe Smith & Nephew is more favorable than ConvaTec Group.
55.7% of Smith & Nephew shares are owned by institutional investors. Comparatively, 66.6% of ConvaTec Group shares are owned by institutional investors. 0.2% of Smith & Nephew shares are owned by insiders. Comparatively, 20.2% of ConvaTec Group shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
In the previous week, Smith & Nephew and Smith & Nephew both had 1 articles in the media. Smith & Nephew's average media sentiment score of 0.20 beat ConvaTec Group's score of 0.10 indicating that Smith & Nephew is being referred to more favorably in the media.
Summary
ConvaTec Group beats Smith & Nephew on 12 of the 19 factors compared between the two stocks.
Get Smith & Nephew News Delivered to You Automatically
Sign up to receive the latest news and ratings for SN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding SN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartThis chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Smith & Nephew Competitors List
Related Companies and Tools